Clinical Trial Update: VAY736 in Combination With Ibrutinib in Patients With CLL on Ibrutinib [Phase 1]

View source ↗

Summary

This Phase 1 trial evaluated VAY736 in combination with ibrutinib in patients with chronic lymphocytic leukemia who were on ibrutinib. The study has been termin…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Chronic Lymphocytic Leukemia

Drugs mentioned

• IMBRUVICA (IBRUTINIB)
• VAY736

Snippet

Sponsor: Novartis Pharmaceuticals | Conditions: Chronic Lymphocytic Leukemia (CLL) | Phase 1 | Status: TERMINATED | Results posted: 2025-05-13